TGFB1 and fatty liver disease: The VSL#3 probiotic treatment attenuated liver fibrosis in the MCD-fed mice, without affecting the steatohepatitis and hepatic steatosis, by upregulation of the anti-fibrotic transforming growth factor β (TGF-β) pseudoreceptor, Bambi [41].